ArticleClinical rheumatology2010
Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease.
Article in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review.Rheumatology international · 2019Pooled it
- Association of Vasculitis and Familial Mediterranean Fever.Frontiers in immunology · 2019Pooled it
- Association between MEFV Mutations M694V and M680I and Behçet's Disease: A Meta-Analysis.PloS one · 2015Pooled it
- Idiopathic AA amyloidosis presenting with initial abdominal pain: a case report and literature review.Frontiers in medicine · 2025Article
- Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Concurrence of familial Mediterranean fever and Behçet's disease: a case report and review of the literature.Journal of medical case reports · 2023Review
- Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas.Inflammation · 2023Article
- Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.Frontiers in immunology · 2021Review
- The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.Frontiers in immunology · 2020Review
- The off-label use of anakinra in pediatric systemic autoinflammatory diseases.Therapeutic advances in musculoskeletal disease · 2020Review
- Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).Orphanet journal of rare diseases · 2019Review
- The role of interleukin-1 in general pathology.Inflammation and regeneration · 2019Review
- The Future of IL-1 Targeting in Kidney Disease.Drugs · 2018Review
- Canakinumab treatment in children with familial Mediterranean fever: report from a single center.Rheumatology international · 2018Article
- Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.Rheumatology international · 2018Review
- The effect of anakinra on retinal function in isolated perfused vertebrate retina.Journal of current ophthalmology · 2017Article
- Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.Clinical rheumatology · 2017Observational
- Update on the Medical Management of Gastrointestinal Behçet's Disease.Mediators of inflammation · 2017Review
- The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever.Molecular and cellular pediatrics · 2016Article
- Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.Rheumatology (Oxford, England) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean fever (FMF) is associated with mutations in the gene coding for pyrin which lead to accentuated innate immune responses resulting in increased production of IL-1. We present a teenager who had severe FMF and Behçet's disease and developed moderate proteinuria. Renal biopsy showed secondary amyloidosis. Anakinra was started at 1 mg/kg/day subcutaneously along with colchicine treatment. The clinical response was excellent. Acute phase reactants decreased. The level of proteinuria and renal functions remained stable and the hypoalbuminemia returned to normal. Her clinical and laboratory symptoms returned when anakinra had to be stopped at 6 months. Thus, the drug was restarted and she is now clinically in excellent condition a year after the start of therapy. She has normal renal functions, normal serum proteins, and normal acute-phase reactants. However, recently, after 18 months of anakinra treatment, her proteinuria gradually increased and albumin levels decreased. We suggest that anti-IL-1 treatment is beneficial for the suppression of inflammation; however, long-term studies are needed to understand whether progressive renal disease will be prevented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.